Life Sciences Co-Chair Quoted on FDA Targeting More Genetic Testing Firms
Bloomberg BNA’s Medical Devices Law & Industry Report
quotes life sciences partner Gregory Levine
(Washington, D.C.) in a Dec. 10 article that examines the FDA’s increased monitoring of companies marketing direct-to-consumer drug metabolism genetic tests. Mr. Levine explains that the effect of the letters to genetic test makers is to inform them that they may be marketing an illegal product, but the FDA is not using a warning letter at this stage.